Insider Transactions in Q1 2025 at Atea Pharmaceuticals, Inc. (AVIR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Wayne Foster EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,062
-19.4%
|
$36,186
$3.06 P/Share
|
|
Jan 31
2025
|
Wayne Foster EVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+11.4%
|
-
|
|
Jan 31
2025
|
Wayne Foster EVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,333
+38.08%
|
-
|
|
Jan 31
2025
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
88,601
-22.75%
|
$265,803
$3.06 P/Share
|
|
Jan 31
2025
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
99,517
+20.35%
|
-
|
|
Jan 31
2025
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
173,467
+37.43%
|
-
|
|
Jan 31
2025
|
Andrea Corcoran |
SELL
Payment of exercise price or tax liability
|
Direct |
16,102
-2.2%
|
$48,306
$3.06 P/Share
|
|
Jan 31
2025
|
Andrea Corcoran |
BUY
Grant, award, or other acquisition
|
Direct |
10,500
+1.41%
|
-
|
|
Jan 31
2025
|
Andrea Corcoran |
BUY
Exercise of conversion of derivative security
|
Direct |
44,367
+5.78%
|
-
|
|
Jan 31
2025
|
Maria Arantxa Horga Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,071
-20.89%
|
$48,213
$3.06 P/Share
|
|
Jan 31
2025
|
Maria Arantxa Horga Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,750
+11.25%
|
-
|
|
Jan 31
2025
|
Maria Arantxa Horga Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,533
+38.2%
|
-
|
|
Jan 31
2025
|
John Vavricka Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,517
-18.11%
|
$34,551
$3.06 P/Share
|
|
Jan 31
2025
|
John Vavricka Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+12.09%
|
-
|
|
Jan 31
2025
|
John Vavricka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,333
+37.8%
|
-
|
|
Jan 31
2025
|
Janet Mj Hammond Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,134
-14.8%
|
$42,402
$3.06 P/Share
|
|
Jan 31
2025
|
Janet Mj Hammond Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+10.54%
|
-
|
|
Jan 31
2025
|
Janet Mj Hammond Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,800
+35.71%
|
-
|
|
Jan 16
2025
|
Franklin M Berger |
SELL
Open market or private purchase
|
Direct |
10,000
-2.05%
|
$30,000
$3.36 P/Share
|
|
Jan 15
2025
|
Franklin M Berger |
SELL
Open market or private purchase
|
Direct |
15,000
-3.11%
|
$45,000
$3.19 P/Share
|